Refine by
Surgical Environment Articles & Analysis
7 news found
Caresyntax, the leading vendor of enterprise-scale data-driven surgical intelligence solutions to make surgery safer and smarter, today announced its highlights and achievements of 2023, as the company has continued its strong growth journey. Dennis Kogan, co-founder, and CEO: “Caresyntax celebrated its 10-year anniversary in 2023 and accelerated our journey of innovation and expansion ...
Today we are announcing the successful completion of urological surgeries with Dexter® – the first and only on-demand robotic surgery platform. In a world-first, Dr. Dominik Böhlen carried out a series of urological procedures using our novel, Swiss-made surgical robot. Dr. Böhlen and his team leveraged Dexter to assist them in the most difficult work steps during various ...
Human factors and usability are becoming more and more prevalent in the design and development process. So much so, that many organisations are placing a focus on the human factors element of their product development. But, is it a necessary inclusion or simply an added benefit? At eg technology, we live and breathe integrated end-to-end development. So, for us, the answer is simple. Human ...
New View Surgical, Inc., a medical device company developing proprietary imaging and access technologies for minimally invasive surgery (MIS), announced today that it received 510(k) clearance from the U.S. Food and Drug Administration for its VisionPort™ System. The VisionPort™ imaging and access system simplifies laparoscopic procedures for hospitals and provides surgeon-controlled ...
VEO Ophthalmics, LLC announced today that, in honor of Rare Disease Day, it is collaborating with the Masket Foundation to raise awareness of aniridia and treatment options for aniridia. Aniridia is a serious ophthalmic rare disease in which a patient’s iris does not develop properly. VEO Ophthalmics is the U.S. distributor for the CUSTOMFLEX® ARTIFICIALIRIS, a custom-made artificial ...
VEO Ophthalmics, LLC, today announced that the CUSTOMFLEX® ARTIFICIALIRIS has been approved by the Center for Medicare and Medicaid Services (CMS) for transitional pass‐through payment status, effective January 1, 2020. The HCPCS code for the CUSTOMFLEX® ARTIFICIALIRIS that is associated with pass‐through payment is: C1839 Iris prosthesis. The approval by CMS for transitional ...
VEO Ophthalmics, LLC, today announced the launch of the CUSTOMFLEX ® ARTIFICIALIRIS, the first iris prosthesis available in the United States. The surgically implanted device received FDA approval on May 30, 2018 for use in children and adults for the treatment of iris defects resulting from congenital aniridia, acquired defects or other conditions associated with a completely or partially ...